Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition.
Diana CalarasAlexander G MathioudakisZsófia LázárAlexandru CorlateanuPublished in: Biomedicines (2023)
Combined pulmonary fibrosis and emphysema (CPFE) is a clinical syndrome characterized by upper lobe emphysema and lower lobe fibrosis manifested by exercise hypoxemia, normal lung volumes, and severe reduction of diffusion capacity of carbon monoxide. It has varying prevalence worldwide with a male predominance, and with smoking history of more than 40 pack-years being a common risk factor. The unique imaging features of CPFE emphasize its distinct entity, aiding in the timely detection of pulmonary hypertension and lung cancer, both of which are common complications. High-resolution computed tomography (HRCT) is an important diagnostic and prognostic tool, while lung cancer is an independent factor that alters the prognosis in CPFE patients. Treatment options for CPFE are limited, but smoking cessation, usual treatments of pulmonary fibrosis and emphysema, and avoidance of environmental exposures are encouraged.
Keyphrases
- chronic kidney disease
- pulmonary fibrosis
- end stage renal disease
- smoking cessation
- high resolution
- risk factors
- computed tomography
- pulmonary hypertension
- replacement therapy
- magnetic resonance imaging
- air pollution
- early onset
- high intensity
- mass spectrometry
- physical activity
- pulmonary arterial hypertension
- newly diagnosed
- ejection fraction
- risk assessment
- human health
- prognostic factors
- high speed
- body composition
- tandem mass spectrometry
- patient reported outcomes
- liquid chromatography